500,000 Blood Pressure Drug Bottles Recalled Over Carcinogen Concerns
Over 500,000 bottles of blood pressure medication are under recall due to contamination with a carcinogenic substance. Teva Pharmaceuticals USA, based in New Jersey, announced this recall for prazosin hydrochloride capsules earlier this month.
FDA Recall Classification
The U.S. Food and Drug Administration (FDA) has classified this recall as a Class II risk. This classification indicates that using the medication may lead to “temporary or medically reversible adverse health consequences.”
Details of the Recall
The recall specifically involves capsules of prazosin hydrochloride at various dosages:
- 1-milligram capsules
- 2-milligram capsules
- 5-milligram capsules
These capsules were distributed in bottles containing 100, 250, 500, and 1,000 capsules. Their expiration dates range from October 2025 to February 2027.
Contamination Findings
Testing has revealed that these capsules contain levels of “N-nitroso Prazosin impurity C” exceeding the safety limits set by the Carcinogenic Potency Categorization Approach (CPCA). This finding prompted the recall to ensure consumer safety.
What to Do If You Have This Medication
Currently, the FDA has not provided specific instructions on how consumers should dispose of the affected medication. Patients are advised to monitor any health changes and consult with their healthcare providers.
For further updates on this recall and its implications, stay informed through El-Balad.
